MARKET

IMDX

IMDX

Insight Molecular Diagnostics Inc.
NASDAQ
2.590
-0.970
-27.25%
Opening 14:08 03/30 EDT
OPEN
3.480
PREV CLOSE
3.560
HIGH
3.660
LOW
2.575
VOLUME
235.70K
TURNOVER
--
52 WEEK HIGH
8.51
52 WEEK LOW
2.330
MARKET CAP
83.32M
P/E (TTM)
-1.5717
1D
5D
1M
3M
1Y
5Y
1D
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 1h ago
Weekly Report: what happened at IMDX last week (0323-0327)?
Weekly Report · 7h ago
Analysts Are Bullish on Top Healthcare Stocks: Insight Molecular Diagnostics (IMDX), Tango Therapeutics (TNGX)
TipRanks · 3d ago
Buy Rating on IMDX Driven by Strong GraftAssure Traction, Upcoming FDA Catalyst, and Solid Balance Sheet
TipRanks · 3d ago
Insight Molecular Diagnostics outlines $2B annual market opportunity and signals rapid commercialization push for GraftAssureDx
Seeking Alpha · 3d ago
Insight Molecular Diagnostics submits GraftAssureDx for FDA review
TipRanks · 3d ago
Insight Molecular Diagnostics reports Q4 EPS (27c) vs. (28c) last year
TipRanks · 3d ago
Insight Molecular Diagnostics Files GraftAssureDx For Kidney Transplant Rejection Testing For FDA Review
Benzinga · 3d ago
More
About IMDX
Insight Molecular Diagnostics Inc., formerly Oncocyte Corporation, is a molecular diagnostics technology company. The Company's technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is in the process of rebranding its VitaGraft assay (also known as VitaGraft Kidney), which is a lab developed test, under the name GraftAssureCore. The Company's transplant products include GraftAssureCore, GraftAssureDx, GraftAssureIQ. Its oncology products include DetermaCNI, DetermaIO, and OncoTIME. GraftAssureCore is a clinical blood-based solid organ transplantation monitoring test. GraftAssureIQ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. OncoTIME enables research on the tumor immune microenvironment.

Webull offers Insight Molecular Diagnostics Inc stock information, including NASDAQ: IMDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMDX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMDX stock methods without spending real money on the virtual paper trading platform.